Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563479 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
A Phase 3 study of HPV-Related Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
- 9
- Study locations
NCT06563479: Recruiting Phase 3 study of HPV-Related Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06563479 is a Phase 3 study of HPV-Related Squamous Cell Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 291 participants, above the 181-participant average among 6 other HPV-Related Squamous Cell Carcinoma trials with a reported enrollment target (61% higher). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06563479, a Phase 3 study of HPV-Related Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
- 9
- Study locations
Study Summary
The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the following: * Whether a lower dose of radiation in combination with standard chemotherapy causes fewer side effects than the standard dose of radiation therapy in combination with standard chemotherapy * How the study approaches (lower dose of radiation therapy + standard chemotherapy and standard dose of radiation therapy + standard chemotherapy) affect participants' quality of life. The researchers will measure quality of life by having participants fill out questionnaires.
Conditions Studied
Interventions
- OTHER Assessments
- COMBINATION_PRODUCT Chemoradiation
- DIAGNOSTIC_TEST FMISO-PET Scan
Study Locations (9)
New York
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Connecticut
- Hartford Healthcare (Data Collection Only) - Hartford
Florida
- Baptist Alliance MCI (Data Collection Only) - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06563479
The ClinicalTrials.gov registry entry for NCT06563479 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 6 other HPV-Related Squamous Cell Carcinoma trials with a reported enrollment target (61% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV-Related Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Assessments is the first listed.
NCT06563479 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06563479 about?
NCT06563479 is a clinical study titled "A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer". The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the fo...
What is the current status of trial NCT06563479?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2024-08-19. Estimated completion is 2027-08.
What conditions does trial NCT06563479 study?
This clinical trial studies the following conditions: HPV-Related Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06563479?
The interventions under investigation include: Assessments (OTHER), Chemoradiation (COMBINATION_PRODUCT), FMISO-PET Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06563479?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563479 being conducted?
This trial has 9 study locations across Connecticut, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV-Related Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
RECRUITING · Phase 2
-
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
RECRUITING · Phase 2
-
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
De-Escalation Therapy for Human Papillomavirus Negative Disease
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.